Skip to main content
    S

    Standard Biotools Inc (LAB)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.62
    -0.09 (-12.21%)

    Market Cap: $279.27M

    Last updated: Nov 17, 2026 at 11:02 AM ET

    Standard Biotools Inc (LAB) Earnings: Report Dates and Results

    Updated Nov 3, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Standard Biotools reported EPS of -$0.06, below the -$0.01 estimate. It beat the EPS estimate in 1 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    38%(15/39)
    Avg Surprise
    -32.48%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.02
    Range-$0.02 - -$0.02
    2 analysts
    Revenue Consensus
    $21.21M
    Range$20.58M - $22.05M
    2 analysts

    Next Report

    LAB's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    LAB Earnings Call

    The latest LAB earnings call transcript on file is labeled 2025Q1.

    Read the 2025Q1 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, LAB beat 15, missed 20 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $19.39M, down 0.8% from $19.55M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.06-$0.01N/A-500.00%MissN/A10 up, 0 downNov 3, 2026$19.39M
    Jun 30, 2026-$0.05-$0.03-$0.03 - -$0.03-66.67%MissN/A11 up, 0 downAug 5, 2026$20.10M
    Mar 31, 2026-$0.02-$0.02-$0.02 - -$0.020.00%In lineN/A20 up, 1 downMay 5, 2026$21.15M
    Dec 31, 2025$0.07-$0.05N/A+226.08%BeatN/A21 up, 0 downFeb 24, 2026$3.22M
    Sep 30, 2025-$0.04-$0.02-$0.02 - -$0.02-100.00%MissN/A11 up, 0 downNov 4, 2025$19.55M
    Jun 30, 2025-$0.04-$0.04-$0.04 - -$0.040.00%In lineN/A20 up, 0 downAug 11, 2025$21.76M
    Mar 31, 2025-$0.05-$0.04-$0.04 - -$0.04-25.00%MissN/A20 up, 0 downMay 6, 2025$20.22M
    Dec 31, 2024-$0.05-$0.03-$0.03 - -$0.03-64.67%MissN/A20 up, 0 downFeb 26, 2025$890000
    Sep 30, 2024-$0.03-$0.07N/A+57.14%BeatN/A30 up, 0 downOct 30, 2024$22.09M
    Jun 30, 2024-$0.08-$0.07N/A-14.29%MissN/A20 up, 0 downJul 31, 2024$22.49M
    Mar 31, 2024-$0.24-$0.10N/A-140.00%MissN/AN/A0 up, 0 downMay 8, 2024$45.54M
    Dec 31, 2023-$0.25-$0.13N/A-92.31%MissN/A10 up, 0 downFeb 28, 2024$28.19M
    Sep 30, 2023-$0.14-$0.12N/A-16.67%MissN/AN/A0 up, 0 downNov 7, 2023$25.37M
    Jun 30, 2023-$0.14-$0.10N/A-40.00%MissN/AN/A0 up, 0 downAug 8, 2023$27.67M
    Mar 31, 2023-$0.21-$0.06N/A-250.00%MissN/AN/A0 up, 0 downMay 9, 2023$25.12M
    Dec 31, 2022-$0.26-$0.28N/A+7.14%BeatN/AN/A0 up, 0 downFeb 14, 2023$27.02M
    Sep 30, 2022-$0.37-$0.13N/A-184.62%MissN/AN/A0 up, 0 downNov 8, 2022$25.65M
    Jun 30, 2022-$0.33-$0.15N/A-120.00%MissN/AN/A0 up, 0 downAug 8, 2022$18.78M
    Mar 31, 2022-$0.25-$0.18N/A-38.89%MissN/AN/A0 up, 0 downMay 5, 2022$26.50M
    Dec 31, 2021-$0.12-$0.28N/A+57.14%BeatN/AN/AN/AFeb 17, 2022$38.27M
    Sep 30, 2021-$0.07-$0.11N/A+36.36%Beat-333.3%N/AN/ANov 8, 2021$28.50M
    Jun 30, 2021-$0.12-$0.08N/A-50.00%MissN/AN/AN/AAug 5, 2021$31.02M
    Mar 31, 2021-$0.15-$0.04N/A-275.00%MissN/AN/AN/AMay 6, 2021$32.79M
    Dec 31, 2020-$0.13$0.01N/AN/AN/AN/AN/AN/AFeb 10, 2021$44.61M
    Sep 30, 2020$0.03-$0.11N/A+127.27%BeatN/AN/AN/ANov 5, 2020$39.86M
    Jun 30, 2020-$0.07-$0.14N/A+50.00%BeatN/AN/AN/AAug 6, 2020$26.06M
    Mar 31, 2020-$0.13-$0.10N/A-30.00%MissN/AN/AN/AMay 7, 2020$27.62M
    Dec 31, 2019-$0.03-$0.09N/A+66.67%BeatN/AN/AN/AFeb 10, 2020$32.44M
    Sep 30, 2019-$0.09-$0.09N/A0.00%In lineN/AN/AN/ANov 5, 2019$26.50M
    Jun 30, 2019-$0.10-$0.07N/A-42.86%MissN/AN/AN/AAug 1, 2019$28.20M
    Mar 31, 2019-$0.14-$0.10N/A-40.00%MissN/AN/AN/AMay 2, 2019$30.11M
    Dec 31, 2018-$0.06-$0.19N/A+68.42%BeatN/AN/AN/AFeb 7, 2019N/A
    Sep 30, 2018-$0.13-$0.18N/A+27.78%BeatN/AN/AN/ANov 1, 2018$53.20M
    Jun 30, 2018-$0.23-$0.23N/A0.00%In lineN/AN/AN/AAug 2, 2018$48.20M
    Mar 31, 2018-$0.21-$0.30N/A+30.00%BeatN/AN/AN/AMay 3, 2018$66.20M
    Dec 31, 2017-$0.15-$0.25N/A+40.00%BeatN/AN/AN/AFeb 8, 2018$27.75M
    Sep 30, 2017-$0.25-$0.31N/A+19.35%BeatN/AN/AN/ANov 2, 2017$24.75M
    Jun 30, 2017-$0.31-$0.34N/A+8.82%BeatN/AN/AN/AAug 3, 2017$23.91M
    Mar 31, 2017-$0.33-$0.56N/A+41.07%BeatN/AN/AN/AMay 4, 2017$25.53M
    Dec 31, 2016-$0.32-$0.23N/A-39.13%MissN/AN/AN/AFeb 8, 2017$114.09M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.06, after -$0.40 the year before. It was -$1.44 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.06N/A
    Dec 31, 2024-$0.40N/A
    Dec 31, 2023-$0.74N/A
    Dec 31, 2022-$1.21N/A
    Dec 31, 2021-$0.46N/A
    Dec 31, 2020-$0.30N/A
    Dec 31, 2019-$0.36N/A
    Dec 31, 2018-$0.63N/A
    Dec 31, 2017-$1.04N/A
    Dec 31, 2016-$1.44N/A

    Earnings Calls

    The 4 most recent earnings calls are listed below; the latest, 2025Q1 for the period ended Mar 31, 2025, runs about 4,900 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2025Q1Mar 31, 20254,8917
    2024Q4Dec 31, 20245,4787
    2024Q3Sep 30, 20244,4966
    2024Q2Jun 30, 20245,3137

    2025Q1 Earnings Call

    Opening remarks

    John Graziano VP of IR Good day and welcome to the Standard BioTools, Inc., First Quarter 2025 Financial Results Conference Call. Please note this event is being recorded. I would now like to turn the conference over to John Graziano, Vice President of Investor Relations. Please go ahead.

    Michael Egholm President & CEO Thank you, John. Good afternoon, everyone, and welcome to Standard BioTools' first quarter 2025 earnings call. Joining me today is Alex Kim, our Chief Financial Officer. Before we begin, I want to thank our customers, employees, and investors. Your support is what fuels our work and drives our mission to set a new standard in life sciences, empower researchers, accelerate in discovery, all while delivering long-term value to our shareholders. Standard BioTools delivered a solid first quarter with results on plan and in line despite a choppy operating backdrop. Execution continues to improve as we build rigor across the organization, guided by lean principles through our Standard BioTools Business System or just SBS. As operators, we're staying grounded in fundamentals, focusing on what we can control, managing with precision, and driving toward profitability. Before diving into the details, it's worth stepping back for a moment. While the broader environment remains dynamic, we're navigating it from a position of strength with a diversified portfolio, a disciplined operating model, healthy balance sheet, and a team that's getting sharper quarter after quarter as forecast accuracy improves and consistency in how we run the business grows. We are particularly pleased with our strategic foothold in proteomics and a series of recent high-impact product launches. Last week at the American Association of Cancer Research's annual meeting, or AACR, we announced a new SomaScan offering that will pair well with the highly anticipated distributed NGS-based Illumina partner solution. Together, these advancements expand our reach and push the boundaries of what's possible in translational and clinical research. From the outside, the macro backdrop may still cloud the picture, but inside we're strong. Our diversified business and life sciences allows us to operate multiple levels to navigate the waters, including a patient and disciplined M&A strategy, which is benefiting from a growing number of compelling assets and opportunities. With that, let's turn to the numbers. In Q1, while not growth, we executed to plan and delivered $40.8 million in revenue. This was down 10% year-over-year as the market got worse against last year's Q1, and we had elevated backlog to start 2024. Despite this and not enough to wave the all-clear flag, we have seen encouraging traction in capital expenditures, which strengthened our instrument business, which is also helped by a favorable year-over-year comp.

    Frequently Asked Questions About LAB

    Did LAB beat earnings estimates last quarter?

    No. Standard Biotools reported EPS of -$0.06 for the quarter ended Sep 30, 2026, below the -$0.01 estimate by 500.00%.

    What EPS do analysts expect from LAB next quarter?

    The consensus EPS estimate for Standard Biotools for the quarter ending Dec 31, 2026 is -$0.02 from 2 analysts, with estimates from -$0.02 to -$0.02.

    How often does LAB beat earnings estimates?

    Standard Biotools beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -66.28%.